Rhythm Pharmaceuticals, Inc. (RYTM)

Rhythm Pharmaceuticals' stock has been impacted by several events in the past six months. Positive Phase 2 trial results for bivamelagon in treating acquired hypothalamic obesity were announced. The FDA accepted the sNDA for setmelanotide in acquired hypothalamic obesity. The company reported its Q2 2025 financial results, with global revenue increasing by 29% but missing EPS estimates. An upsized public offering of common stock was completed, raising approximately $189.2 million. The company's share price saw a significant increase of 116.87% between October 18, 2024, and October 17, 2025.

Information directly addressing demand seasonality for Rhythm Pharmaceuticals' products and services is not explicitly available. However, the company's financial reporting indicates consistent growth in patient numbers and revenue, suggesting a steady increase in demand rather than significant seasonality. An increase in cash burn from Q4 to Q1 was a seasonal occurrence due to company-wide cash bonuses, which relates to internal financial operations rather than product demand.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for rare neuroendocrine diseases, particularly rare genetic diseases of obesity. Their lead product, IMCIVREE (setmelanotide), is an FDA-approved melanocortin-4 receptor (MC4R) agonist for chronic weight management in patients with specific genetic deficiencies and Bardet-Biedl syndrome (BBS). The company is also developing other MC4R agonists and small molecules for related conditions.

Rhythm Pharmaceuticals has a global presence, generating revenue from the United States and international markets. IMCIVREE is commercially available in North America, Europe, and over 20 countries internationally. The company aims to expand its global reach through regulatory approvals and launches in additional countries.

Rhythm Pharmaceuticals' brand reputation is mixed but generally leans positive, based on analyst ratings. Citigroup reiterated an "outperform" rating, and Leerink Partners raised the rating to "strong-buy". Wall Street Zen raised its rating from "sell" to "hold", and Wells Fargo & Company boosted its price target. However, Weiss Ratings reaffirmed a "sell" rating. The stock has an average rating of "Moderate Buy" with a consensus price target of $107.21. Missing analysts' consensus estimates for earnings per share in Q2 2025 could have affected the company's reputation.

Rhythm Pharmaceuticals has a significant institutional ownership presence, with institutional investors holding approximately 87.82% to 96.98% of the company's stock. Insiders own about 6.10% to 13.89% of the company, while retail investors hold a smaller percentage, around 0.72% to 59.58%. Major institutional owners include BlackRock, Inc., Baker Bros. Advisors Lp, and RA Capital Management, L.P. Felix Baker owns the most shares among individual investors.